In fact, results of the RELATIVITY-047 study [49] indicate a significant improvement of Progression-Free Survival (PFS) in melanoma patients treated with nivolumab + relatlimab, where the relatlimab combination with anti-PD-1 drugs is a strategy to overcome drug resistance [50]. The gene discussed is PDCD1; the disease is melanoma.